Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05231 (
interleukin-6
)
23,907
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Apobec-1 complementation factor
(
ACF
) is the RNA binding subunit of a core complex that mediates C to U RNA editing of apolipoprotein B (apoB) mRNA. Targeted deletion of the murine Acf gene is early embryonic lethal and Acf(-/-) blastocysts fail to implant and proliferate, suggesting that
ACF
plays a key role in cell growth and differentiation. Here we demonstrate that heterozygous Acf(+/-) mice exhibit decreased proliferation and impaired liver mass restitution following partial hepatectomy (PH). To pursue the mechanism of impaired liver regeneration we examined activation of
interleukin-6
(
IL-6
) a key cytokine required for induction of hepatocyte proliferation following PH. Peak induction of hepatic
IL-6
mRNA abundance post PH was attenuated >80% in heterozygous Acf(+/-) mice, along with decreased serum
IL-6
levels.
IL-6
secretion from isolated Kupffer cells (KC) was 2-fold greater in wild-type compared with heterozygous Acf(+/-) mice. Recombinant
ACF
bound an AU-rich region in the
IL-6
3'-untranslated region with high affinity and
IL-6
mRNA half-life was significantly shorter in KC isolated from Acf(+/-) mice compared with wild-type controls. These findings suggest that
ACF
regulates liver regeneration following PH at least in part by controlling the stability of
IL-6
mRNA. The results further suggest a new RNA target and an unanticipated physiological function for
ACF
beyond apoB RNA editing.
...
PMID:Apobec-1 complementation factor modulates liver regeneration by post-transcriptional regulation of interleukin-6 mRNA stability. 2040 9
Apobec-1 complementation factor
(
A1CF
) is a heterogeneous nuclear ribonuceloprotein (hnRNP) and mediates apolipoprotein-B mRNA editing.
A1CF
can promote the regeneration of the liver by post-transcriptionally stabilizing
Interleukin-6
(
IL-6
) mRNA. It also contains two transcriptional variants-A1CF64 and A1CF65, distinguished by the appearance of a 24-nucleotide motif which contributes to the corresponding eight-amino acid motif of EIYMNVPV. For the first time, we demonstrated that the EIYMNVPV motif was essential for
A1CF
nucleus localization,
A1CF
deficient of the EIYMNVPV motif,
A1CF
(-8aa) showed cytoplasm distribution. More importantly, we found that
A1CF
(-8aa), but not its full-length counterpart, can promote proliferation of MDA-MB-231 cells accompanied with increased level of
IL-6
mRNA. Furthermore, silencing of
IL-6
attenuated
A1CF
(-8aa)-induced proliferation in MDA-MB-231 cells. In conclusion, notably, these findings suggest that
A1CF
(-8aa) promoted proliferation of MDA-MB-231 cells in vitro viewing
IL-6
as a target. Thus, the EIYMNVPV motif could be developed as a potential target for basal-like breast cancer therapy.
...
PMID:EIYMNVPV Motif is Essential for A1CF Nucleus Localization and A1CF (-8aa) Promotes Proliferation of MDA-MB-231 Cells via Up-Regulation of IL-6. 2723 8